Amicus Therapeutics (NASDAQ:FOLD) expects Galafold sales in Q3 to be ~$48M, up 133% from a year ago and above consensus of ~$45M.
It is raising the lower end of its full-year range
for Galafold sales to $170M – 180M from $160M – 180M. It expects to end
the year with more than $420M in cash which should extend its runway
into H1 2022.
The webcast of its Analyst Day is currently underway.
Shares up 6% premarket on light volume.
https://seekingalpha.com/news/3504981-amicus-6-percent-premarket-preliminary-q3-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.